Requirement for retinal screening in patients taking hydroxychloroquine and chloroquine Dahkki Lotery, A, Yusuf, I

Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration Dahkki Chakravarthy, U, Harding, S, Rogers, C, Downes, S, Lotery, A, Wordsworth, S, Reeves, B

Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Dahkki Chakravarthy, U, Harding, S, Rogers, C, Downes, S, Lotery, A, Wordsworth, S, Reeves, B

Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN randomized trial Dahkki Chakravarthy, U, Harding, S, Rogers, C, Downes, S, Lotery, A, Wordsworth, S, Reeves, B

Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial Dahkki Chakravarthy, U, Harding, S, Rogers, C, Downes, S, Lotery, A, Culliford, L, Reeves, B

Pharmacogenetic Associations with Vascular Endothelial Growth Factor Inhibition in Participants with Neovascular Age-Related Macular Degeneration in the IVAN Study Dahkki Lotery, A, Cree, A, Gibson, J, Ennis, S, Downes, S, Harding, S, Rogers, C, Reeves, B, Chakravarthy, U

Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age-related macular degeneration in the ivan study Dahkki Lotery, A, Gibson, J, Cree, A, Downes, S, Harding, S, Rogers, C, Reeves, B, Ennis, S, Chakravarthy, U

Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial. Dahkki Dakin, H, Wordsworth, S, Rogers, C, Abangma, G, Raftery, J, Harding, S, Lotery, A, Downes, S, Chakravarthy, U, Reeves, B

Cohort profile: design and methods in the eye and vision consortium of UK Biobank Dahkki Chua, S, Thomas, D, Allen, N, Lotery, A, Desai, P, Patel, P, Muthy, Z, Sudlow, C, Peto, T, Khaw, P, Foster, P, Uk Biobank Eye & Vision Consortium

Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial. Dahkki Maclaren, R, Groppe, M, Barnard, A, Cottriall, C, Tolmachova, T, Seymour, L, Clark, K, During, M, Cremers, F, Black, G, Lotery, A, Downes, S, Webster, A, Seabra, M

Visual acuity after retinal gene therapy for Choroideremia Dahkki Edwards, T, Jolly, J, Groppe, M, Barnard, A, Cottriall, C, Tolmachova, T, Black, G, Webster, A, Lotery, A, Holder, G, Xue, K, Downes, S, Simunovic, M, Seabra, M, MacLaren, R

Missense mutations in a retinal pigment epithelium protein, bestrophin-1, cause retinitis pigmentosa. Dahkki Davidson, A, Millar, I, Urquhart, J, Burgess-Mullan, R, Shweikh, Y, Parry, N, O'Sullivan, J, Maher, G, McKibbin, M, Downes, S, Lotery, A, Jacobson, S, Brown, P, Black, G, Manson, F

Beneficial effects on vision in patients undergoing retinal gene therapy for choroideremia Dahkki Xue, K, Jolly, J, Barnard, A, Rudenko, A, Salvetti, A, Patrício, M, Edwards, T, Groppe, M, Orlans, H, Tolmachova, T, Black, G, Webster, A, Lotery, A, Holder, G, Downes, S, Seabra, M, MacLaren, R

Retinal gene therapy in patients with choroideremia: Initial fi ndings from a phase 1/2 clinical trial Dahkki MacLaren, R, MacLaren, R, MacLaren, R, Groppe, M, Groppe, M, Groppe, M, Barnard, A, Cottriall, C, Tolmachova, T, Seymour, L, Reed Clark, K, During, M, Cremers, F, Black, G, Lotery, A, Downes, S, Downes, S, Webster, A, Webster, A, Seabra, M, Seabra, M